EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Diagnosis, treatment, and prognosis of primary intraocular lymphoma: Single‐center real‐world clinical experience

Gi-June Min iD, Tong Yoon Kim, Young-Woo Jeon iD, Joo Hyun O, Byung-Ock Choi, Gyeongsin Park, Young-Hoon Park, Seok-Goo Cho iD

Cancer Medicine · 2023

DOI: 10.1002/cam4.5567 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Medicine, 2023. Verfasst von Gi-June Min und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Catholic University Lymphoma Group, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul…. Hauptthemen laut MEDLINE: Intraocular Lymphoma, Central Nervous System Neoplasms. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The diagnosis and management of primary intraocular lymphoma (PIOL) remain challenging. This study identified factors indicative of PIOL, described treatment outcomes, and determined modalities to prevent relapse.

Methods

We included 21 PIOL‐diagnosed patients, seven via cytology, 12 via genetic evaluation, and two via interleukin (IL) level measurements, who underwent vitrectomy and received local intravitreal methotrexate (IV‐MTX) injection. Clinical outcomes, including treatment response and relapse, were compared between patients receiving IV‐MTX alone (n = 13) or IV‐MTX with systemic high‐dose methotrexate (HD‐MTX) as prophylaxis (n = 8).

Results

Twelve ophthalmologic and eight central nervous system (CNS) relapse cases within a median of 20.3 and 11.6 months were shown, regardless of the treatment modalities, with a median progression‐free survival of 21.3 (95% confidence interval, 9.5–36.7) months. There was no difference in demographic characteristics between the two groups, except with the poorer performance status in patients in the HD‐MTX prophylaxis group. Furthermore, patients demonstrated rapid elevations in the vitreous fluid IL‐10/IL‐6 cytokine ratio before ophthalmologic and CNS relapse. Therefore, diagnosis should be based on clinical signs and assisted by vitrectomy, cytologic, molecular, and cytokine studies.

Conclusion

For PIOL, aggressive systemic treatment equivalent to that of primary CNS lymphoma (PCNSL) is recommended because solely HD‐MTX did not prevent or delay CNS relapse. To prevent PIOL relapse in the CNS efficiently, prospective trials with large numbers of patients and advanced therapeutic regimens are necessary. Furthermore, regular clinical follow‐up is crucial, and the IL‐10/IL‐6 ratio can help evaluate relapse promptly.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Intraocular LymphomaCentral Nervous System NeoplasmsHumansMethotrexateInterleukin-10Prospective StudiesInterleukin-6Neoplasm Recurrence, LocalTreatment OutcomeRetrospective Studies

Stichwörter der Autor:innen

CNS relapselocal intravitreal methotrexateprimary intraocular lymphomasystemic high-dose methotrexate

Substanzen

MethotrexateInterleukin-10Interleukin-6

Autor:innen und Institutionen

  • Department of Hematology, Catholic University Lymphoma Group, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.
  • Department of Hematology, Catholic University Lymphoma Group, Yeouido St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.
  • Department of Nuclear Medicine, Catholic University Lymphoma Group, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.
  • Department of Radiation Oncology, Catholic University Lymphoma Group, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.
  • Department of Hospital Pathology, Catholic University Lymphoma Group, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.
  • Department of Ophthalmology and Visual Science, Catholic University Lymphoma Group, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.

ORCID-Profile: Gi-June Min, Young-Woo Jeon, Seok-Goo Cho

Zitieren

APA

Min, G. J., Kim, T. Y., Jeon, Y. W., O, J. H., Choi, B. O., Park, G., Park, Y. H., & Cho, S. G. (2023). Diagnosis, treatment, and prognosis of primary intraocular lymphoma: Single‐center real‐world clinical experience. Cancer Medicine. https://doi.org/10.1002/cam4.5567

Vancouver

Min GJ, Kim TY, Jeon YW, O JH, Choi BO, Park G, et al. Diagnosis, treatment, and prognosis of primary intraocular lymphoma: Single‐center real‐world clinical experience. Cancer Medicine. 2023. doi:10.1002/cam4.5567

BibTeX
@article{Min2023,
  author = {Min, Gi-June and Kim, Tong Yoon and Jeon, Young-Woo and O, Joo Hyun and Choi, Byung-Ock and Park, Gyeongsin and Park, Young-Hoon and Cho, Seok-Goo},
  title = {Diagnosis, treatment, and prognosis of primary intraocular lymphoma: Single‐center real‐world clinical experience},
  journal = {Cancer Medicine},
  year = {2023},
  doi = {10.1002/cam4.5567}
}
Kostenlos starten →